LRMR
Price
$3.91
Change
+$0.22 (+5.96%)
Updated
Aug 22 closing price
Capitalization
334.66M
87 days until earnings call
OCUL
Price
$12.30
Change
+$0.17 (+1.40%)
Updated
Aug 22 closing price
Capitalization
2.14B
78 days until earnings call
Interact to see
Advertisement

LRMR vs OCUL

Header iconLRMR vs OCUL Comparison
Open Charts LRMR vs OCULBanner chart's image
Larimar Therapeutics
Price$3.91
Change+$0.22 (+5.96%)
Volume$1.42M
Capitalization334.66M
Ocular Therapeutix
Price$12.30
Change+$0.17 (+1.40%)
Volume$1.41M
Capitalization2.14B
LRMR vs OCUL Comparison Chart in %
Loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. OCUL commentary
Aug 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 24, 2025
Stock price -- (LRMR: $3.91 vs. OCUL: $12.30)
Brand notoriety: LRMR and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 101% vs. OCUL: 63%
Market capitalization -- LRMR: $334.66M vs. OCUL: $2.14B
LRMR [@Biotechnology] is valued at $334.66M. OCUL’s [@Biotechnology] market capitalization is $2.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.31B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, LRMR is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • LRMR’s TA Score: 4 bullish, 4 bearish.
  • OCUL’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than OCUL.

Price Growth

LRMR (@Biotechnology) experienced а -2.49% price change this week, while OCUL (@Biotechnology) price change was -2.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +18.06%, and the average quarterly price growth was +26.94%.

Reported Earning Dates

LRMR is expected to report earnings on Nov 18, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.14B) has a higher market cap than LRMR($335M). OCUL YTD gains are higher at: 44.028 vs. LRMR (1.034). LRMR has higher annual earnings (EBITDA): -108.21M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. LRMR (139M). LRMR has less debt than OCUL: LRMR (4.61M) vs OCUL (76.9M). OCUL has higher revenues than LRMR: OCUL (56.7M) vs LRMR (0).
LRMROCULLRMR / OCUL
Capitalization335M2.14B16%
EBITDA-108.21M-200.5M54%
Gain YTD1.03444.0282%
P/E RatioN/AN/A-
Revenue056.7M-
Total Cash139M391M36%
Total Debt4.61M76.9M6%
FUNDAMENTALS RATINGS
LRMR vs OCUL: Fundamental Ratings
LRMR
OCUL
OUTLOOK RATING
1..100
7758
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
54
Fair valued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4038
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
21n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (31) in the null industry is in the same range as OCUL (54) in the Pharmaceuticals Other industry. This means that LRMR’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (83) in the Pharmaceuticals Other industry is in the same range as LRMR (100) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as LRMR (100) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

OCUL's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as LRMR (40) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as LRMR (100) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMROCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
86%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSXPX59.002.45
+4.33%
Goldman Sachs Small Cp Val Insghts P
FSCRX25.450.82
+3.33%
Fidelity Small Cap Discovery
EMAYX18.360.30
+1.66%
Gabelli Entpr Mergers & Acquisitions Y
USSPX80.781.21
+1.52%
Victory 500 Index Member
IRVSX26.110.34
+1.32%
Voya Russell Large Cap Value Idx Port S

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+5.96%
EYPT - LRMR
48%
Loosely correlated
+1.98%
SYRE - LRMR
48%
Loosely correlated
+3.58%
OCUL - LRMR
48%
Loosely correlated
+1.40%
ERAS - LRMR
47%
Loosely correlated
+6.67%
ACLX - LRMR
47%
Loosely correlated
-0.68%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+1.40%
EYPT - OCUL
65%
Loosely correlated
+1.98%
CRNX - OCUL
55%
Loosely correlated
+5.17%
IDYA - OCUL
55%
Loosely correlated
+1.99%
DNLI - OCUL
55%
Loosely correlated
+1.71%
RVMD - OCUL
55%
Loosely correlated
+1.45%
More